Kintor Pharmaceutical (HKG:9939) completed the enrollment of the first subject in the phase 3 stage pivotal clinical trial of its KX-826 tincture 1% for treating male adult hair loss, specifically the androgenetic alopecia, in China.
The trial is a multi-center, randomized, double-blind, vehicle-controlled study and adopts a 2-in-1 design for the evaluation of efficacy and safety of KX-826 tincture 1.0% for the treatment of hair loss, a Monday Hong Kong bourse filing said.
The phase 3 trials are expected to enroll 666 patients in China within five months in 25 clinical research centers in the country.
The trial comprises a 24-week treatment phase followed by a month of safety observation, the filing said.